Cytokinetics Inc (CYTK)
65.27
+0.93
(+1.45%)
USD |
NASDAQ |
May 03, 16:00
65.33
+0.06
(+0.09%)
After-Hours: 20:00
Cytokinetics Revenue (Quarterly): 1.672M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.672M |
September 30, 2023 | 0.378M |
June 30, 2023 | 0.867M |
March 31, 2023 | 4.613M |
December 31, 2022 | 1.957M |
September 30, 2022 | 2.515M |
June 30, 2022 | 88.97M |
March 31, 2022 | 1.148M |
December 31, 2021 | 55.60M |
September 30, 2021 | 5.437M |
June 30, 2021 | 2.843M |
March 31, 2021 | 6.548M |
December 31, 2020 | 6.722M |
September 30, 2020 | 41.69M |
June 30, 2020 | 3.593M |
March 31, 2020 | 3.825M |
December 31, 2019 | 5.212M |
September 30, 2019 | 6.055M |
June 30, 2019 | 7.137M |
March 31, 2019 | 8.464M |
December 31, 2018 | 9.377M |
September 30, 2018 | 10.64M |
June 30, 2018 | 6.215M |
March 31, 2018 | 5.268M |
December 31, 2017 | -0.018M |
Date | Value |
---|---|
September 30, 2017 | 6.18M |
June 30, 2017 | 3.053M |
March 31, 2017 | 4.153M |
December 31, 2016 | 33.14M |
September 30, 2016 | 59.05M |
June 30, 2016 | 5.802M |
March 31, 2016 | 8.421M |
December 31, 2015 | 9.757M |
September 30, 2015 | 7.945M |
June 30, 2015 | 6.542M |
March 31, 2015 | 4.414M |
December 31, 2014 | 21.76M |
September 30, 2014 | 9.415M |
June 30, 2014 | 7.788M |
March 31, 2014 | 7.979M |
December 31, 2013 | 24.35M |
September 30, 2013 | 4.469M |
June 30, 2013 | 1.009M |
March 31, 2013 | 0.821M |
December 31, 2012 | 2.184M |
September 30, 2012 | 1.714M |
June 30, 2012 | 1.841M |
March 31, 2012 | 1.82M |
December 31, 2011 | 0.757M |
September 30, 2011 | 1.427M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.378M
Minimum
Sep 2023
88.97M
Maximum
Jun 2022
12.99M
Average
4.613M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
Amgen Inc | 7.447B |
Johnson & Johnson | 21.38B |
Eli Lilly and Co | 8.768B |
Viking Therapeutics Inc | -- |
Madrigal Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -136.90M |
Total Expenses (Quarterly) | 129.09M |
EPS Diluted (Quarterly) | -1.38 |
Enterprise Value | 6.726B |
Gross Profit Margin (Quarterly) | -4.98K% |
Profit Margin (Quarterly) | -8.19K% |
Earnings Yield | -8.35% |
Normalized Earnings Yield | -8.350 |